title: [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
abstract: OBJECTIVE
  To compare the efficacy and adverse effects between arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL).
  
  
  METHODS
  The clinical data of 71 patients with newly diagnosed APL were retrospectively analyzed. Two groups were classified according to the induction regimens, namely ATO group (n = 41) and ATRA group (n = 30). The complete remission (CR) rate and the time to CR were compared between these two groups.
  
  
  RESULTS
  The CR rate was 97.5% in ATO group and 93.3% in ATRA group (P > 0.05). The median time to CR was 29 days (21-45 days) in ATO group, which was significantly shorter than 38.5 days (24-63 days) in ATRA group (P < 0.001). Retinoic acid syndrome occurred in 52.9% of patients treated with ATRA, which affected the further use of ATRA.
  
  
  CONCLUSIONS
  Both ATO and ATRA have high response rates for newly diagnosed patients with APL. Compared with ATRA, ATO induction therapy has shorter time to achieve CR and less adverse effects, and therefore may be the first-line therapy for APL.
authors.affiliation: Department of Hematology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
authors.forename: Li
authors.initials: L
authors.lastname: Jiao
authors.forename: Shu-Jie
authors.initials: SJ
authors.lastname: Wang
authors.forename: Jun-Ling
authors.initials: JL
authors.lastname: Zhuang
authors.forename: Yong-Qiang
authors.initials: YQ
authors.lastname: Zhao
authors.forename: Dao-Bin
authors.initials: DB
authors.lastname: Zhou
authors.forename: Ying
authors.initials: Y
authors.lastname: Xu
authors.forename: Bing
authors.initials: B
authors.lastname: Han
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Ming-Hui
authors.initials: MH
authors.lastname: Duan
authors.forename: Nong
authors.initials: N
authors.lastname: Zou
authors.forename: Tie-Nan
authors.initials: TN
authors.lastname: Zhu
authors.forename: Ti
authors.initials: T
authors.lastname: Shen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide